Anna C Winnicki, Melanie H Dietrich, Lee M Yeoh, Lenore L Carias, Wanlapa Roobsoong, Chiara L Drago, Alyssa N Malachin, Karli R Redinger, Lionel Brice Feufack-Donfack, Lea Baldor, Nicolai C Jung, Olivia S McLaine, Yelenna Skomorovska-Prokvolit, Agnes Orban, D Herbert Opi, Jetsumon Sattabongkot, Wai-Hong Tham, Jean Popovici, James G Beeson, Jürgen Bosch, Christopher L King
New therapeutics are a priority for preventing and eliminating Plasmodium vivax (Pv) malaria because of its easy transmissibility and dormant stages in the liver. Relapses due to the dormant liver stages are the major contributor to reoccurring Pv. Therefore, therapies that reduce the establishment of dormant parasites and blood-stage infection are important for controlling this geographically widespread parasite. Here, we isolated 12 human monoclonal antibodies (humAbs) from the plasma of a Pv-exposed individual that recognized Pv apical membrane antigen 1 (PvAMA1)...
February 9, 2024: bioRxiv